Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liproca Depot in Localized Prostate Cancer
NCT02341404Phase 2Completed
- Sponsor
- LIDDS AB
- Start
- May 2012
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 2-hydroxyflutamide in prostate cancer (PCa), sponsored by LIDDS AB. Primary endpoints: Characterization and quantification of histopathological measurement of tumour tissue obtained from diagnostic biopsy at Day 1, Characterization and quantification of histopathological measurement of tumour tissue in surgical specimens obtained from patients undergoing prostatectomy at 6 weeks and 1 more. Started May 2012; status: completed.
02
Drugs
2-hydroxyflutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02341404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341404.